

# **Dialogues in Contraception<sup>®</sup>, Volume 11, Issue 2 References**

Please click on the Reference Section below to go directly to that section's reference list. You can also scroll from this page to view all of the references.

## **Reference Sections**

[Management of Unscheduled Bleeding With Hormonal Methods](#)

[Venus Thromboembolism and Cardiovascular Disease: Hormonal Contraception](#)

[Contraception and Obesity: Effectiveness](#)

## Management of Unscheduled Bleeding With Hormonal Methods

1. Mishell DR Jr, Guillebaud J, Westhoff C, et al. Combined hormonal contraceptive trials: variable data collection and bleeding assessment methodologies influence study outcomes and physician perception. *Contraception*. 2007;75:4-10.
2. Mishell DR Jr, Guillebaud J, Westhoff C, et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. *Contraception*. 2007;75:11-15.
3. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. *Am J Obstet Gynecol*. 1998;179:577-582.
4. Tolley E, Loza S, Kafafi L, Cummings S. The impact of menstrual side effects on contraceptive discontinuation: findings from a longitudinal study in Cairo, Egypt. *Int Fam Plan Perspect*. 2005;31:15-23.
5. The ESHRE Capri Workshop Group. Continuation rates for oral contraceptives and hormone replacement therapy. *Hum Reprod*. 2000;15:1865-1871.
6. Gilliam ML, Warden M, Goldstein C, Tapia B. Concerns about contraceptive side effects among young Latinas: a focus-group approach. *Contraception*. 2004;70:299-305.
7. Clark LR, Barnes-Harper KT, Ginsburg KR, Holmes WC, Schwarz DF. Menstrual irregularity from hormonal contraception: a cause of reproductive health concerns in minority adolescent young women. *Contraception*. 2006;74:214-219.
8. Clark LR. Will the pill make me sterile? Addressing reproductive health concerns and strategies to improve adherence to hormonal contraceptive regimens in adolescent girls. *J Pediatr Adolesc Gynecol*. 2001;14:153-162.
9. Huber LR, Hogue CJ, Stein AD, et al. Contraceptive use and discontinuation: findings from the contraceptive history, initiation, and choice study. *Am J Obstet Gynecol*. 2006;194:1290-1295.
10. Rosenberg MJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature. *Adv Contracept*. 1992;8(suppl 1):35-45.
11. Rosenberg MJ, Waugh MS, Long S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. *J Reprod Med*. 1995;40:355-360.
12. Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus >20 mcg estrogen combined oral contraceptives for contraception. *Cochrane Database Syst Rev*. 2005;CD003989.
13. Speroff L, Darney PD. Oral contraception. In: *A Clinical Guide for Contraception*. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:Chapter 2.

14. Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. *Contraception*. 2001;63:289-295.
15. LaGuardia KD, Shangold G, Fisher A, Friedman A, Kafrisen M, for the Norgestimate Study Group. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol. *Contraception*. 2003;67:431-437.
16. Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa™ (desogestrel/ethinyl estradiol) and Ortho-Novum® 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. *Contraception*. 2000;61:295-302.
17. Foidart J-M, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. *Eur J Contracept Reprod Health Care*. 2000;5:124-134.
18. Poindexter AN, Burkman R, Fisher AC, LaGuardia KD. Cycle control, tolerability, and satisfaction among women switching from 30-35 µg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 µg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen® LO. *Int J Fertil*. 2003;48:163-172.
19. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. *Contraception*. 2000;61:105-111.
20. Heinz M. Menstrual patterns under hormonal contraception in adolescent girls and young women. *Pediatr Endocrinol Rev*. 2006;3(suppl 1):146-149.
21. Anderson FD, Hait H, and the Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. *Contraception*. 2003;68:89-96.
22. Anderson FD, Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. *Am J Obstet Gynecol*. 2006;195:92-96.
23. Foidart JM, Sulak PJ, Schellschmidt I, Zimmermann D. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. *Contraception*. 2006;73:34-40.
24. Ziemann M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system: the analysis of pooled data. *Fertil Steril*. 2002;77(suppl 2):S13-S18.
25. Audet M-C, Moreau M, Koltun WD, et al, for the ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal

contraceptive patch vs an oral contraceptive: a randomized controlled trial. *JAMA*. 2001;285:2347-2354.

26. Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. *Am J Obstet Gynecol*. 2002;186:389-395.
27. Westhoff C, Osborne LM, Schafer JE, Morroni C. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive. *Obstet Gynecol*. 2005;106:89-96.
28. Croxatto HB, Urbancsek J, Massai R, Bennink HC, van Beek A, and the Implanon® Study Group. A multicentre efficacy and safety study of the single contraceptive implant Implanon®. *Hum Reprod*. 1999;14:976-981.
29. Otero Flores JB, Balderas ML, Bonilla MC, Vázquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. *Int J Gynaecol Obstet*. 2005;90:228-233.
30. Smith OP, Critchley HO. Progestogen only contraception and endometrial break through bleeding. *Angiogenesis*. 2005;8:117-126.
31. d'Arcangues C. Management of vaginal bleeding irregularities induced by progestin-only contraceptives. *Hum Reprod*. 2000;15(suppl 3):24-29.
32. Speroff L, Darney PD. Implant contraception. In: *A Clinical Guide for Contraception*. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005: Chapter 5.
33. Speroff L, Darney PD. Injectable contraception. In: *A Clinical Guide for Contraception*. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005: Chapter 6.
34. Schwallie PC, Assenzo JR. Contraceptive use—efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. *Fertil Steril*. 1973;24:331-339.
35. Arias RD, Jain JK, Brucker C, Ross D, Ray A. Changes in bleeding patterns with depot medroxyprogesterone acetate subcutaneous injection 104 mg. *Contraception*. 2006;74:234-238.
36. Shoupe D, Mishell DR Jr, Bopp BL, Fielding M. The significance of bleeding patterns in Norplant implant users. *Obstet Gynecol*. 1991;77:256-260.
37. Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. *Contraception*. 2002;65:129-132.

38. Andersson K, Odland V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. *Contraception*. 1994;49:56-72.
39. Sivin I, Stern J, for the International Committee for Contraception Research. Health during prolonged use of levonorgestrel 20 µgd and the Copper TCU 380Ag intrauterine contraceptive devices: a multicenter study. *Fertil Steril*. 1994;61:70-77.
40. Broome M, Fotherby K. Clinical experience with the progestogen-only pill. *Contraception*. 1990;42:489-495.
41. Speroff L, Darney PD. Special uses of oral contraception. Emergency contraception: the progestin-only minipill. In: *A Clinical Guide for Contraception*. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005: Chapter 3.
42. Lohr PA, Creinin MD. Oral contraceptives and breakthrough bleeding: what patients need to know. *J Fam Pract*. 2006;55:872-880.
43. Rönnerdag M, Odland V. Late bleeding problems with the levonorgestrel-releasing intrauterine system: evaluation of the endometrial cavity. *Contraception*. 2007;75:268-270.
44. Canto De Cetina TE, Canto P, Luna MO. Effect of counseling to improve compliance in Mexican women receiving depot-medroxyprogesterone acetate. *Contraception*. 2001;63:143-146.
45. Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. *Am J Obstet Gynecol*. 1999;180:S276-S279.
46. Burke AE, Blumenthal PD. Successful use of oral contraceptives. *Semin Reprod Med*. 2001;19:313-321.
47. Freeman S. Nondaily hormonal contraception: considerations in contraceptive choice and patient counseling. *J Am Acad Nurse Pract*. 2004;16:226-238.
48. Grossman MP, Nakajima ST. Menstrual cycle bleeding patterns in cigarette smokers. *Contraception*. 2006;73:562-565.
49. Mishra GD, Dobson AJ, Schofield MJ. Cigarette smoking, menstrual symptoms and miscarriage among young women. *Aust N Z J Public Health*. 2000;24:413-420.
50. Brown S, Vessey M, Stratton I. The influence of method of contraception and cigarette smoking on menstrual patterns. *Br J Obstet Gynaecol*. 1988;95:905-910.
51. Rosenberg MJ, Waugh MS, Stevens CM. Smoking and cycle control among oral contraceptive users. *Am J Obstet Gynecol*. 1996;174:628-632.
52. Rosenberg MJ, Waugh MS, Higgins JE. The effect of desogestrel, gestodene, and other factors on spotting and bleeding. *Contraception*. 1996;53:85-90.

53. Westhoff C, Morroni C, Kerns J, Murphy PA. Bleeding patterns after immediate vs conventional oral contraceptive initiation: a randomized, controlled trial. *Fertil Steril*. 2003;79:322-329.
54. Meckstroth KR, Darney PD. Implant contraception. *Semin Reprod Med*. 2001;19:339-354.
55. Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. *Am J Obstet Gynecol*. 1996;175:787-792.
56. Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. *Drug Saf*. 2004;27:75-90.
57. Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. *Cochrane Database Syst Rev*. 2002;CD000400.
58. Weisberg E, Hickey M, Palmer D, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. *Hum Reprod*. 2006;21:295-302.
59. Li R, Luo X, Archer DF, Chegini N. Doxycycline alters the expression of matrix metalloproteases in the endometrial cells exposed to ovarian steroids and pro-inflammatory cytokine. *J Reprod Immunol*. 2007;73:118-129.
60. Chegini N, Luo X, Pan Q, Rhoton-Vlasak A, Archer DF. Endometrial expression of epithelial neutrophil-activating peptide-78 during the menstrual cycle or in progestin-only contraceptive users with breakthrough bleeding and the influence of doxycycline therapy. *Hum Reprod*. 2007;22:427-433.
61. Li R, Luo X, Pan Q, et al. Doxycycline alters the expression of inflammatory and immune-related cytokines and chemokines in human endometrial cells: implication in irregular uterine bleeding. *Hum Reprod*. 2006;21:2555-2563.
62. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. *Cochrane Database Syst Rev*. 2000;CD000249.
63. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. *BMJ*. 1996;313:579-582.
64. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. *Drugs*. 1999;57:1005-1032.
65. Sulak PJ, Kuehl TJ, Coffee A, Willis S. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. *Am J Obstet Gynecol*. 2006;195:935-941.

## **Venus Thromboembolism and Cardiovascular Disease: Hormonal Contraception**

1. James AH, Tapson VF, Goldhaber SZ. Thrombosis during pregnancy and the postpartum period. *Am J Obstet Gynecol.* 2005;193:216-219.
2. James AH, Bushnell CD, Jamison MG, Myers ER. Incidence and risk factors for stroke in pregnancy and the puerperium. *Obstet Gynecol.* 2005;106:509-516.
3. James AH, Jamison MG, Biswas MS, Brancazio LR, Swamy GK, Myers ER. Acute myocardial infarction in pregnancy: a United States population-based study. *Circulation.* 2006;113:1564-1571.
4. World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. *World Health Organ Tech Rep Ser.* 1998;877:i-89.
5. Kamphuisen PW, Rosendaal FR. Thrombophilia screening: a matter of debate. *Neth J Med.* 2004;62:180-187.
6. Brouwer J-LP, Veeger NJGM, Kluin-Nelemans HC, van der Meer J. The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. *Ann Intern Med.* 2006;145:807-815.
7. Heinemann LA, DoMinh T, Assmann A, et al. VTE risk assessment—a prognostic Model: BATER Cohort Study of young women. *Thromb J.* 2005;3:1-10.
8. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ III. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. *Ann Intern Med.* 2005;143:697-706.
9. Farmer RDT, Preston TD. The risk of venous thromboembolism associated with low oestrogen oral contraceptives. *J Obstet Gynaecol.* 1995;15:195-200.
10. Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. *Arch Intern Med.* 2004;164:2260-2265.
11. Spannagl M, Heinemann LAJ, DoMinh T, Assmann A, Schramm W, Schürmann R. Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: a community-based cohort study [review]. *Thromb J.* 2005;3:8.
12. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis [review]. *Hum Genet.* 2001;109:369-384.
13. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. *Thromb Haemost.* 2003;89:493-498.

14. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. *JAMA*. 1997;277:642-645.
15. Bank I, Libourel EJ, Middeldorp S, et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. *Arch Intern Med*. 2004;164:1932-1937.
16. Bank I, Libourel EJ, Middeldorp S, et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. *J Thromb Haemost*. 2005;3:79-84.
17. Emmerich J, Rosendaal FR, Cattaneo M, et al, for the Study Group for Pooled-Analysis in Venous Thromboembolism. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. *Thromb Haemost*. 2001;86:809-816.
18. Coppens M, van de Poel MH, Bank I, et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. *Blood*. 2006;108:2604-2607.
19. Afeltra A, Vadacca M, Conti L, et al. Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. *Arthritis Rheum*. 2005;53:452-459.
20. Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. *J Vasc Surg*. 2007;45:335-342.
21. Perez-Rodriguez E, Jimenez D, Diaz G, et al. Incidence of air travel-related pulmonary embolism at the Madrid-Barajas airport. *Arch Intern Med*. 2003;163:2766-2770.
22. Martinelli I, Taioli E, Battaglioli T, et al. Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. *Arch Intern Med*. 2003;163:2771-2774.
23. Cannegieter SC, Doggen CJ, van Houwelingen HC, Rosendaal FR. Travel-related venous thrombosis: results from a large population-based case control study (MEGA study). *PLoS Med*. 2006;3:1258-1265.
24. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*. 2007;115:e69-171.

25. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. 2003;42:1206-1252.
26. Bittner V. Women and coronary heart disease risk factors. *J Cardiovasc Risk*. 2002;9:315-322.
27. Expert Panel on the Identification, Evaluation, and Treatment of Overweight Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. *Am J Clin Nutr*. 1998;68:899-917.
28. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. *Arch Intern Med*. 2004;164:1422-1426.
29. Smith SC Jr, Haslam D. Abdominal obesity, waist circumference and cardio-metabolic risk: awareness among primary care physicians, the general population and patients at risk—the Shape of the Nations survey. *Curr Med Res Opin*. 2007;23:29-47.
30. Toloza SMA, Uribe AG, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. *Arthritis Rheum*. 2004;50:3947-3957.
31. Pullmann R Jr, Skerenova M, Lukac J, et al. Factor V Leiden and prothrombin G20210A mutations and the risk of atherothrombotic events in systemic lupus erythematosus. *Clin Appl Thromb Hemost*. 2004;10:233-238.
32. Frostegard J. Atherosclerosis in patients with autoimmune disorders. *Arterioscler Thromb Vasc Biol*. 2005;25:1776-1785.
33. Austin MA, McKnight B, Edwards KL, et al. Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. *Circulation*. 2000;101:2777-2782.
34. Chang CL, Donaghy M, Poulter N, and World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: case-control study. *Br Med J*. 1999;318:13-18.
35. Donaghy M, Chang CL, Poulter N, on behalf of the European Collaborators of The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. *J Neurol Neurosurg Psychiatry*. 2002;73:747-750.
36. Scher AI, Terwindt GM, Picavet HSJ, Verschuren WMM, Ferrari MD, Launer LJ. Cardiovascular risk factors and migraine: the GEM population-based study. *Neurology*. 2005;64:614-620.

37. Heinemann LAJ. Emerging evidence on oral contraceptives and arterial disease. *Contraception*. 2000;62:29S-36S.
38. Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance—United States, 1991-1999. *MMWR CDC Surveill Summ*. 2003;52:1-8.
39. Heinemann LAJ, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. *Contraception*. 2007;75:328-336.
40. Westhoff CL. Oral contraceptives and venous thromboembolism: should epidemiologic associations drive clinical decision making? *Contraception*. 1996;54:1-3.
41. Shulman LP, Goldzieher JW. The truth about oral contraceptives and venous thromboembolism. *J Reprod Med*. 2003;48:930-938.
42. World Health Organization. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. *Lancet*. 1995;346:1575-1582.
43. Hannaford P. Cardiovascular events associated with different combined oral contraceptives: a review of current data. *Drug Saf*. 2000;22:361-371.
44. Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. *Arch Intern Med*. 2001;161:1065-1070.
45. World Health Organization. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. *Lancet*. 1996;348:505-510.
46. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. *N Engl J Med*. 1996;335:8-15.
47. Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. *Circulation*. 1998;98:1058-1063.
48. Schwartz SM, Petitti DB, Siscovick DS, et al. Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. *Stroke*. 1998;29:2277-2284.
49. Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: Final results from the European Active Surveillance study on Oral Contraceptives (EURAS-OC) based on 142,475 women-years of observation. *Contraception*. 2007;75:344-354.

50. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 µg of ethinyl estradiol. *Contraception*. 2006;73:223-228.
51. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. *Obstet Gynecol*. 2007;109:339-346.
52. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. *Contraception*. 2006;73:566-570.
53. World Health Organization. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives: results of an international, multicenter, case-control study. *Contraception*. 1998;57:315-324.
54. Heinemann LAJ, Assmann A, DoMinh T, Garbe E, and the Transnational Research Group on Oral Contraceptives and the Health of Young Women. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. *Eur J Contracept Reprod Health Care*. 1999;4:67-73.
55. Yasmin [package insert]. Wayne, NJ: Berlex Laboratories; 2003.
56. ORTHO EVRA [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2006.
57. Ortho Tri-Cyclen Lo [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc.; 2004.
58. NuvaRing [package insert]. Roseland, NJ: Organon USA Inc.; 2005.
59. World Health Organization. Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use. 3rd ed. Geneva, Switzerland: World Health Organization; 2004.
60. Comp PC. Should coagulation tests be used to determine which oral contraceptive users have an increased risk of thrombophlebitis [commentary]? *Contraception*. 2006;73:4-5.
61. Speroff L, Darney PD. The post-partum period, breastfeeding and contraception. In: *A Clinical Guide for Contraception*. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005: chap 10.
62. Implanon [package insert]. Roseland, NJ: Organon USA Inc.; 2006.

## Contraception and Obesity: Effectiveness

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. *JAMA*. 2006;295:1549-1555.
2. Centers for Disease Control and Prevention. About BMI for adults. Available at: [http://www.cdc.gov/nccdphp/dnpa/bmi/adult\\_BMI/about\\_adult\\_BMI.htm](http://www.cdc.gov/nccdphp/dnpa/bmi/adult_BMI/about_adult_BMI.htm). Accessed March 27, 2007.
3. Centers for Disease Control and Prevention. State-specific prevalence of obesity among adults—United States, 2005. *MMWR Morb Mortal Wkly Rep*. 2006;55:985-988.
4. National Center for Health Statistics. CDC Growth Charts: United States. Body mass index-for-age percentiles: girls, 2 to 20 years. Available at: <http://www.cdc.gov/nchs/about/major/nhanes/growthcharts/charts.htm>. Accessed March 16, 2007.
5. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991-1998. *JAMA*. 1999;282:1519-1522.
6. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. *Cochrane Database Syst Rev*. 2006;CD003987.
7. Coney P, Washenik K, Langley RGB, DiGiovanna JJ, Harrison DD. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. *Contraception*. 2001;63:297-302.
8. Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. *Contraception*. 1995;52:215-219.
9. Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. *Obstet Gynecol*. 2004;103:359-373.
10. Sibai B, Odlind V, Meador M, Shangold G, Fisher A, Creasy G. A comparative assessment of ORTHO EVRA™/EVRA™ to placebo patch effects on body weight [abstract]. *Fertil Steril*. 2001;76(suppl 1):S188.
11. Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra™/Evra™). *Fertil Steril*. 2002;77(suppl 2):S19-S26.
12. O'Connell KJ, Osborne LM, Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. *Contraception*. 2005;72:323-327.
13. Pelkman C. Hormones and weight change. *J Reprod Med*. 2002;47:791-794.

14. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. *Contraception*. 2004;70:269-275.
15. Anderson FD, Hait H, and the Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. *Contraception*. 2003;68:89-96.
16. Westhoff C, Jain JK, Milsom I, Ray A. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. *Contraception*. 2007;75:261-267.
17. Taneepanichskul S, Reinprayoon D, Jaisamrarn U. Effects of DMPA on weight and blood pressure in long term acceptors. *Contraception*. 1999;59:301-303.
18. Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. *Contraception*. 1995;51:149-153.
19. Holt VL, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling JR. Body mass index, weight, and oral contraceptive failure risk. *Obstet Gynecol*. 2005;105:46-52.
20. Brunner Huber LR, Hogue CJ, Stein AD, Drews C, Zieman M. Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. *Ann Epidemiol*. 2006;16:637-643.
21. Vessey M, Painter R. Oral contraceptive failures and body weight: findings in a large cohort study. *J Fam Plann Reprod Health Care*. 2001;27:90-91.
22. Holt VL, Cushing-Haugen KL, Daling JR. Body weight and risk of oral contraceptive failure. *Obstet Gynecol*. 2002;99:820-827.
23. Creinin MD, Roberts E. Body mass index, weight, and oral contraceptive failure risk. [Letter to the editor]. *Obstet Gynecol*. 2005;105:1492-1493.
24. Brunner LR, Hogue CJ. The role of body weight in oral contraceptive failure: results from the 1995 National Survey of Family Growth. *Ann Epidemiol*. 2005;15:492-499.
25. Brunner Huber LR, Hogue CJ. The association between body weight, unintended pregnancy resulting in a livebirth, and contraception at the time of conception. *Matern Child Health J*. 2005;9:413-420.
26. Dinger JC, Heinemann LAJ, Westhoff C, Cronin M, Schellschmidt I. Contraceptive efficacy of oral contraceptives in real world clinical practice: The impact of age, weight, BMI, dose, and duration of use. Poster presented at: American College of Obstetricians and Gynecologists 55th Annual Clinical Meeting; May 5-9, 2007; San Diego, Calif.

27. Mason M. Pressing to look closer at blood clots and the pill. *New York Times*. February 13, 2007.
28. Ziemann M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system: the analysis of pooled data. *Fertil Steril*. 2002;77(suppl 2):S13-S18.
29. Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa™ (desogestrel/ethinyl estradiol) and Ortho-Novum® 7/7/7 (norethindrone/ethinyl estradiol): a randomized clinical trial. *Contraception*. 2000;61:295-302.
30. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. *Contraception*. 2000;61:105-111.
31. Croxatto HB, Urbancsek J, Massai R, Bennink HC, van Beek A, and the Implanon® Study Group. A multicentre efficacy and safety study of the single contraceptive implant Implanon®. *Hum Reprod*. 1999;14:976-981.
32. Funk S, Miller MM, Mishell D Jr, et al, for The Implanon™ US Study Group. Safety and efficacy of Implanon™, a single-rod implantable contraceptive containing etonogestrel. *Contraception*. 2005;71:319-326.
33. Kaunitz AM, Garceau RJ, Cromie MA, and the Lunelle Study Group. Comparative safety, efficacy, and cycle control of Lunelle™ monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum® 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). *Contraception*. 1999;60:179-187.
34. Archer DF, Maheux R, DelConte A, O'Brien FB; North American Levonorgestrel Study Group. Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 µg levonorgestrel and 20 µg ethinyl estradiol (Alesse®). *Am J Obstet Gynecol*. 1999;181:S39-S44.
35. Nakajima ST, Archer DF, Ellman H. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 µg (Loestrin® 24 Fe). *Contraception*. 2007;75:16-22.
36. Hampton RM, Short M, Bieber E, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. *Contraception*. 2001;63:289-295.
37. Westhoff CL, Anderson FD. Seasonale (30 µg of ethinyl estradiol/150 µg of levonorgestrel) extended-regimen oral contraceptive: efficacy and cycle control by body weight [abstract]. *Contraception*. 2006;74:181-182.
38. Audet M-C, Moreau M, Koltun WD, et al, for the ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal

contraceptive patch vs an oral contraceptive: a randomized controlled trial. *JAMA*. 2001;285:2347-2354.

39. Smallwood GH, Meador ML, Lenihan JP, et al. Efficacy and safety of a transdermal contraceptive system. *Obstet Gynecol*. 2001;98:799-805.
40. Hedon B, Helmerhorst FM, Cronje HS, Shangold G, Fisher A, Creasy G. Comparison of efficacy, cycle control, compliance, and safety in users of a contraceptive patch vs an oral contraceptive [abstract]. *Int J Gynaecol Obstet*. 2000;70(suppl 2):B78.
41. Westhoff C. Higher body weight does not affect NuvaRing<sup>®</sup>'s efficacy. Poster presented at: American College of Obstetricians and Gynecologists 52nd Annual Clinical Meeting; May 1-5, 2004; Philadelphia, Pa.
42. Sivin I. Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. *Drug Saf*. 2003;26:303-335.
43. Merhi ZO. Challenging oral contraception after weight loss by bariatric surgery. *Gynecol Obstet Invest*. 2007;64:100-102.
44. Gerrits EG, Ceulemans R, van Hee R, Hendrickx L, Totté E. Contraceptive treatment after biliopancreatic diversion needs consensus. *Obes Surg*. 2003;13:378-382.
45. Hanker JP. Gastrointestinal disease and oral contraception. *Am J Obstet Gynecol*. 1990;163:2204-2207.